Story thread · 4 reports / 3 sources
Karyopharm shares crater on second Phase 3 flop for Xpovio in endometrial cancer
endpts.com · 11d
Karyopharm’s stock has plummeted after its second attempt to expand its blood cancer medicine Xpovio into endometrial cancer fell short. Late Thursday, the company reported that its latest trial, called XPORT-EC-042 ...
First report: United Therapeutics’ ralinepag meets primary endpoint in phase 3 trial — investing.com, 13d
The coverage
- Karyopharm plummets as Xpovio fails in phase 3 trial for endometrial cancer
seekingalpha.com · 11d
The conversation · 0
Sign in to join the conversation.
No comments yet — start the thread.